Schizophrenia
Conditions
Keywords
magnetic seizure therapy, electroconvulsive therapy, controlled trial
Brief summary
This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety among schizophrenia patients. Half of the participants will be randomized to MST group, while the other half will be randomized to receive electroconvulsive therapy (ECT).
Detailed description
Magnetic seizure therapy (MST) is likely to be an alternative options to electroconvulsive therapy (ECT). Widespread stimulation of cortical and subcortical regions is inevitable for ECT since the substantial impedance of the scalp and skull shuts most of the electrical stimulus away from the brain. Nevertheless, magnetic pulses are capable to focus the stimulus to a specific area of the brain because they can pass the scalp and skull without resistance. In Addition, electric current will penetrate into deeper structures, while magnetic stimulus are only capable to reach a depth of a few centimeters. As a consequence, MST are able to generate focus stimuli on superficial regions of the cortex while ECT can't, which may give MST the capability to produce comparable therapeutic benefits with the absence of apparent cognitive side effects. However, MST and ECT may both works via alterations of cortical inhibition and default mode network.
Interventions
DEVICEMagpro X100
In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
OTHERTreatment as usual (TAU)
Participants will engage in their intpatient treatment program as-usual.
Sponsors
Shanghai Mental Health Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. DSM-5 diagnosis of schizophrenia; 2. convulsive therapy clinically indicated, such as severe psychomotor excitement or retardation, attempts of suicide, being highly aggressive, pharmacotherapy intolerance, and ineffectiveness of antipsychotics; 3. the positive and negative syndrome scale (PANSS)\[20\] score ≥ 60; 4. informed consent in written form.
Exclusion criteria
1. diagnosis of other mental disorders; 2. severe physical diseases, such as stroke, heart failure, liver failure, neoplasm, and immune deficiency; 3. present with a laboratory abnormality that could impact on efficacy of treatments or safety of participants; 4. failure to respond to an adequate trial of ECT lifetime; 5. are pregnant or intend to get pregnant during the study; 6. other conditions that investigators consider to be inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Positive and Negative Syndrome Scale (PANSS) | At baseline and 4-week follow-up | — |
| changes in brain structure | At baseline, the 1 day after the first treatment, and at 4-week follow-up | measured by Magnetic Resonance Imaging (MRI) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in motor threshold (MT) | At baseline and the day after the first treatment | using single-pulse Transcranial Magnetic Stimulation (sTMS) |
| Changes in brain gamma-aminobutyric acid （GABA）levels | At baseline, between the first treatment and the second treatment, and at 4-week follow-up | measured by Magnetic Resonance Spectroscopy (MRS) |
| Changes in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | At baseline and 4-week follow-up | — |
| Changes in auditory evoked potential (AEP) | At baseline and the day after the first treatment | measured by electroencephalogram (EEG) |
| Changes in novel P300 potential | At baseline and the day after the first treatment | measure by electroencephalogram (EEG) |
| Changes in resting state network (RSN) | At baseline, the day after the first treatment, and at 4-week follow-up | measured by Magnetic Resonance Imaging (MRI) |
| Changes in Clinical Global Impressions (CGI) | At baseline and 4-week follow-up | — |
Countries
China
Outcome results
None listed